Hema Dave, MD

Sr. Principal Scientist
Merck & Co., Inc.

Poster(s):

• (360) Real-World Clinical Outcomes and Disease Management Costs among High-Risk Non-Muscle Invasive Bladder Cancer Patients Treated with Bacillus Calmette-Guérin: A SEER-Medicare Analysis
  Wednesday, October 29, 2025